Intralesional Bevacizumab for the Treatment of Recurrent Sinonasal Hemangioma.
Michael R KinzingerE Bradley StrongJoan BernardToby O SteelePublished in: The Annals of otology, rhinology, and laryngology (2018)
This report demonstrates the first reported successful treatment of a sinonasal hemangioma with intralesional bevacizumab. Intralesional bevacizumab confers an additional option for adjuvant treatment of sinonasal hemangiomas. Further evaluation of intralesional bevacizumab in the treatment of these tumors is warranted.
Keyphrases